Advertisements
Feeds:
Posts
Comments

Archive for the ‘Cardiac and Cardiovascular Surgical Procedures’ Category


SNP-based Study on high BMI exposure confirms CVD and DM Risks – no associations with Stroke

Reporter: Aviva Lev-Ari, PhD, RN

Genes Affirm: High BMI Carries Weighty Heart, Diabetes Risk – Mendelian randomization study adds to ‘burgeoning evidence’

by Crystal Phend, Senior Associate Editor, MedPage Today, July 05, 2017

 

The “genetically instrumented” measure of high BMI exposure — calculated based on 93 single-nucleotide polymorphisms associated with BMI in prior genome-wide association studies — was associated with the following risks (odds ratios given per standard deviation higher BMI):

  • Hypertension (OR 1.64, 95% CI 1.48-1.83)
  • Coronary heart disease (CHD; OR 1.35, 95% CI 1.09-1.69)
  • Type 2 diabetes (OR 2.53, 95% CI 2.04-3.13)
  • Systolic blood pressure (β 1.65 mm Hg, 95% CI 0.78-2.52 mm Hg)
  • Diastolic blood pressure (β 1.37 mm Hg, 95% CI 0.88-1.85 mm Hg)

However, there were no associations with stroke, Donald Lyall, PhD, of the University of Glasgow, and colleagues reported online in JAMA Cardiology.

The associations independent of age, sex, Townsend deprivation scores, alcohol intake, and smoking history were found in baseline data from 119,859 participants in the population-based U.K. Biobank who had complete medical, sociodemographic, and genetic data.

“The main advantage of an MR approach is that certain types of study bias can be minimized,” the team noted. “Because DNA is stable and randomly inherited, which helps to mitigate errors from reverse causality and confounding, genetic variation can be used as a proxy for lifetime BMI to overcome limitations such as reverse causality and confounding, a process that hampers observational analyses of obesity and its consequences.”

 

Other related articles published in this Open Access Online Scientific Journal include the following:

9 results for Kindle Store : “Aviva Lev-Ari”

Sort by 
Relevance
Featured
Price: Low to High
Price: High to Low
Avg. Customer Review
Publication Date
  • Product Details

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Tilda Barliya PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly

 

Advertisements

Read Full Post »


Spectranetics, a Technology Leader in Medical Devices for Coronary Intervention, Peripheral Intervention, Lead Management to be acquired by Philips for 1.9 Billion Euros

Reporter and Curator: Aviva Lev-Ari, PhD, RN

 

 

Philips to buy medical device maker Spectranetics for 1.9 billion euros

By Toby Sterling | AMSTERDAM

Dutch healthcare company Philips (PHG.AS) has agreed to buy U.S.-based Spectranetics Corp (SPNC.O), a maker of devices to treat heart disease, for 1.9 billion euros (£1.68 billion) including debt, as it expands its image-guided therapy business.

Spectranetics uses techniques including lasers and tiny drug-covered balloons to clean the insides of veins and arteries that have become clogged due to heart disease.

Philips will pay Spectranetics shareholders $38.50 per share, a 27 percent premium to their closing price on June 27.

Philips Chief Executive Frans van Houten has transformed the former conglomerate into a focused maker of healthcare equipment over the past five years, spinning off its lighting division (LIGHT.AS) and selling most of its remaining consumer products business.

Philips said Spectranetics, which expects sales of around $300 million this year, will continue to grow revenues at double-digit rates and will begin adding to Philips’ earnings in 2018.

SOURCE

http://uk.reuters.com/article/uk-spectranetics-m-a-philips-idUKKBN19J0MZ?em_pos=small&ref=headline&nl_art=1

Home / About Spectranetics / Overview

http://www.spectranetics.com/about/overview/

Spectranetics’ History – 30 years of Innovations and M&A

http://www.spectranetics.com/about/history/

Products

Coronary Intervention

Coronary Artery Disease (CAD) is the leading cause of death among men and women. Each year, one in four deaths are attributed to CAD in the United States, accounting for over a half million lives lost. From scoring balloon technology to laser atherectomy to thrombus aspiration and removal, Spectranetics offers a comprehensive portfolio of solutions to cross, prep and treat compromised vessels. Learn more about CAD by navigating through the tile grid below and exploring the products that are saving lives.

SOURCE

http://www.spectranetics.com/solutions/coronary-intervention/

 

 Peripheral Intervention

Spectranetics is dedicated to helping physicians cross, prep and treat complex clinical challenges of Peripheral Artery Disease, such as Critical Limb Ischemia, Chronic Total Occlusions and In-Stent Restenosis. We provide expert tools, training, ongoing support and patient education so that you can help eradicate restenosis, and amputation and modify all plaque. Explore the tile grid below to learn more about Peripheral Artery Disease and Spectranetics’ comprehensive portfolio of products to successfully treat this challenging cardiovascular condition at every stage.

Products

 SOURCE

Lead Management

Managing cardiac implantable electronic device (CIED) leads has never been more important. Patients with CIEDs are on a lifelong journey, and Spectranetics is there to make sure it’s a healthy one. Making the right decision at the right time, for every patient, is critical. Lives depend on it. Explore the tile grid below to learn more about Lead Management and the products that ensure lead extraction is done safely, responsibly and predictably.

Other related articles published in this Open Access Online Scientific Journal include the following:

Read Full Post »


Off-Label TAVR Procedures: 1 in 10 associated with higher in-hospital 30-day mortality, 1-year mortality was similar in the Off-Label and the On-Label groups

Reporter: Aviva Lev-Ari, PhD, RN

 

UPDATED on 7/10, 2017

FDA clears Medtronic’s CoreValve Evolut TAVR in intermediate risk patients

JULY 10, 2017 BY FINK DENSFORD

http://www.massdevice.com/fda-clears-medtronics-corevalve-evolut-tavr-in-intermediate-risk-patients/?spMailingID=11443122&spUserID=MTU0MTAzNDg3OTA5S0&spJobID=1200865729&spReportId=MTIwMDg2NTcyOQS2

 

 

  • by Nicole Lou, Reporter, MedPage Today/CRTonline.org June 21, 2017

Action Points

  • Off-label transcatheter aortic valve replacement (TAVR) was associated with higher in-hospital, 30-day, and 1-year mortality rates compared with on-label TAVR use, but after adjustment, 1-year mortality was similar in the two groups.
  • Note that approximately one in 10 TAVR patients in the United States have received the procedure for an off-label indication.

Three-quarters of off-label indications were deemed so due to presence of severe aortic or mitral regurgitation or both; one-fifth were off-label because of bicuspid valves.

Successful device implantation was slightly less likely with off-label TAVR (92.9% versus 93.0%, P=0.02). But in-hospital outcomes were the bigger issue for off- versus on-label TAVR:

  • Mortality (6.3% versus 4.7%, P<0.001)
  • Cardiac arrest (6.6% versus 4.8%, P<0.001)
  • Transient ischemic attack (0.5% versus 0.2%, P=0.007)
  • Moderate-to-severe perivalvular leaks (12.4% versus 7.6%, P<0.001)

Mortality was most likely for patients with severe mitral regurgitation as the only off-label indication for TAVR. The authors suggested this is owing to secondary mitral regurgitation caused by left ventricular dilatation.

SOURCE

1 in 10 TAVR Procedures Done Off-Label Despite early risks vs on-label use, ‘acceptable results’ cited from registry

https://www.medpagetoday.com/Cardiology/CHF/66173?xid=nl_mpt_DHE_2017-06-22&eun=g99985d0r&pos=1

Other related TAVR articles published in this Open Access Online Scientific Journal included the following 64 articles:

https://pharmaceuticalintelligence.com/?s=TAVR

 

 

Read Full Post »


Right Internal Carotid Artery Clot Aspiration: 4.5 Minute Thrombectomy Using the ADAPT-FAST Technique and the ACE68 Catheter

Reporter: Aviva Lev-Ari, PhD, RN

 

WATCH VIDEO

http://mus.2.broadcastmed.net/videos/4-5-minute-thrombectomy-using-the-adapt-fast-technique-and-the-ace68-catheter?utm_source=social&utm_medium=facebook&utm_content=Thrombectomy&utm_campaign=mus_7952

Read Full Post »


Less is More: Minimalist Mitral Valve Repair: Expert Opinion of Prem S. Shekar, MD, Chief, Division of Cardiac Surgery, BWH – #7, 2017 Disruptive Dozen at #WMIF17

Reporter: Aviva Lev-Ari, PhD, RN

 

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017  BOSTON, MA • UNITED STATES

11:45 am – 12:45 pm
Boston Scientific Ballroom
Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care
  • Chief of Cardiovascular Medicine, Brigham and Women’s Hospital
  • Associate Professor of Medicine, Harvard Medical School
  • Chief, Cardiology Division, Massachusetts General Hospital
  • Professor of Medicine, Harvard Medical School

12. Aging and Heart Disease: Can we reverse the process?

11.Nanotechnologies for Cardiac Diagnosis and Treatment

10. Breaking the Code: Diagnosis and Therapeutic Potential of RNA

9. Expanding the Pool of Organs for Transplant

8. Finding Cancer therapies without Cardiotoxicity

7. Less is more: Minimalist Mitral Valve Repair

6. Understanding Why exercise works for Just about every thing

5. Power Play: The Future of Implantable Cardiac Devices

4. Adopting the Orphan of Heart Disease

3. Targeting Inflammation in cardiovascular Disease

2. Harnessing Big Data and Deep Learning for Clinical Decision Support

  1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

SOURCE

https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

 

Excerpts from Prem S. Shekar, MD Presentation

The success achieved with TAVR

  1. least traumatic
  2. short recovery
  3. quicker return to normal lifestyle

encouraged Medical devices Manufacturers to develop Mitral Valve Repair technologies to address the large unmet need for percutaneous treatment of patients with Mitral Valve disease:

Mild or Severe (4 Million in the US, alone).

  • Mitral Regurgitation (MR) – imperfect closure of the valve permits blood from LV to return back towards the lungs.

Causes for MR

  1. the degenerative myxomatous disease
  2. senile calcific degenerative disease causing enlargement of the LV, infection or Trauma.
  • Mitral stenosis – narrowing of the valve

Causes for Mitral Stenosis

  1. rheumatic fever
  2. senile calcific degeneration – obstruction to the forward flow of blood resulting in increased fluid pressure inside the lungs.

Symptoms of MR – managed by drugs or Surgery for correction (Open Heart surgery or MIS – both procedures require use of bypass machine, the heart been stopped for the duration of repair/replacement) for Valve Repair or Valve Replacement

  1. shortness of breath
  2. fatigue

Uncorrected Mitral Valve disease can lead to 

  1. irregular heart rhythms
  2. increased risk for stroke
  3. CHF
  4. Death

Transcatheter Mitral Valve Correction

  1. Valve replacement
  2. use of Repair devices on the Mitral leaflets
  3. implantation of neochords
  4. remodeling of the mitral annulus

Comparison of TARV with Transcatheter Mitral Valve Correction

  1. Aortic Valve vs Mitral Valve: difference in complexity and artistic nature of Mitral repair
  2. Ability to perform a Percutaneous repair on a Mitral Valve with same degree of accuracy and reproducibility as a Percutaneous repair on an Aortic Valve — will remain a challenge.
  3. development of advance imaging technologies will play a key role in achieveing success with Percutaneous repair on a Mitral Valve
  4. Percutaneous repair on a Mitral Valve need to overcome the complex structure and integrated relationship with the LV.

Leading Challenges in the Development of Percutaneous repair on a Mitral Valve Technologies

  1. Mitral is a bigger Valve than the Aortic
  2. It is more difficult to access
  3. It is Asymmetrical
  4. It lacks an anatomically well-defined annulus to which to anchor the artificial valve
  5. Its geometry changes throughout the cardiac cycle
  6. Placement of a replacement valve bears the risk of LV outflow tract obstruction

Patient Candidate Profile forPercutaneous repair on a Mitral Valve

  1. Patient with a failed Mitral Valve bioprosthesis – Severe Mitral Valve Disease
  2. Failed Mitral Valve Repairs
  3. Senile calcific degeneration
  4. Mitral Regurgitation unmanaged by medication
  5. Variable surgical risk related to co-morbidities

 

Other related articles on Mirtal Valve Disease covered in this Open Access Online Scientific Journal Include the following:

Search Category:

Cardiovascular Medical Devices: Cardiac Surgery, Cardiothoracic Surgical Procedures and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty – 248 articles

Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? – Last Updated on 4/8/2017

Justin Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

 

Lev-Ari, A. 5/19/2014. Transcatheter Mitral Valve (TMV) Procedures: Centers for Medicare & Medicaid Services (CMS) proposes to cover Transcatheter Mitral Valve Repair (TMVR)

https://pharmaceuticalintelligence.com/2014/05/19/transcatheter-mitral-valve-tmv-procedures-centers-for-medicare-medicaid-services-cms-proposes-to-cover-transcatheter-mitral-valve-repair-tmvr/

 

Lev-Ari, A. 1/26/2014. Transcatheter Valve Competition in the United States: Medtronic CoreValve infringes on Edwards Lifesciences Corp. Transcatheter Device Patents

https://pharmaceuticalintelligence.com/2014/01/26/transcatheter-valve-competition-in-the-united-states-medtronic-corevalve-infringes-on-edwards-lifesciences-corp-transcatheter-device-patents/

 

Lev-Ari, A. 1/26/2014. Developments on the Frontier of Transcatheter Aortic Valve Replacement (TAVR) Devices

https://pharmaceuticalintelligence.com/2014/01/26/developments-on-the-frontier-of-transcatheter-aortic-valve-replacement-tavr-devices/

 

Larry H. Bernstein and
Aviva Lev-Ari 6/23/2013 Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty

https://pharmaceuticalintelligence.com/2013/06/23/comparison-of-cardiothoracic-bypass-and-percutaneous-interventional-catheterization-survivals/

 

Larry H Bernstein and Lev-Ari, A. 6/23/2013 First case in the US: Valve-in-Valve (Aortic and Mitral) Replacements with Transapical Transcatheter Implants – The Use of Transfemoral Devices.

https://pharmaceuticalintelligence.com/2013/06/23/valve-in-valve-replacements-with-transapical-transcatheter-implants/

Larry H Bernstein and  Lev-Ari, A. 6/17/2013 Transcatheter Aortic Valve Replacement (TAVR): Postdilatation to Reduce Paravalvular Regurgitation During TAVR with a Balloon-expandable Valve

https://pharmaceuticalintelligence.com/2013/06/17/postdilatation-to-reduce-paravalvular-regurgitation-during-transcatheter-aortic-valve-replacement/

Larry H Bernstein and Lev-Ari, A. 6/17/2013 Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD)

https://pharmaceuticalintelligence.com/2013/06/17/management-of-difficult-trans-apical-transcatheter-aortic-valve-replacement-in-a-patient-with-severe-and-complex-arterial-disease/

Larry H Bernstein and Lev-Ari, A. 6/18/2013 Ventricular Assist Device (VAD): A Recommended Approach to the Treatment of Intractable Cardiogenic Shock

https://pharmaceuticalintelligence.com/2013/06/18/a-recommended-approach-to-the-treatmnt-of-intractable-cardiogenic-shock/

Larry H Bernstein and Lev-Ari, A.6/20/2013 Phrenic Nerve Stimulation in Patients with Cheyne-Stokes Respiration and Congestive Heart Failure

https://pharmaceuticalintelligence.com/2013/06/20/phrenic-nerve-stimulation-in-patients-with-cheyne-stokes-respiration-and-congestive-heart-failure/

Lev-Ari, A. 2/12/2013 Clinical Trials on transcatheter aortic valve replacement (TAVR) to be conducted by American College of Cardiology and the Society of Thoracic Surgeons

https://pharmaceuticalintelligence.com/2013/02/12/american-college-of-cardiologys-and-the-society-of-thoracic-surgeons-entrance-into-clinical-trials-is-noteworthy-read-more-two-medical-societies-jump-into-clinical-trial-effort-for-tavr-tech-f/

Lev-Ari, A. 12/31/2012 Renal Sympathetic Denervation: Updates on the State of Medicine

https://pharmaceuticalintelligence.com/2012/12/31/renal-sympathetic-denervation-updates-on-the-state-of-medicine/

Lev-Ari, A. 9/2/2012 Imbalance of Autonomic Tone: The Promise of Intravascular Stimulation of Autonomics

https://pharmaceuticalintelligence.com/2012/09/02/imbalance-of-autonomic-tone-the-promise-of-intravascular-stimulation-of-autonomics/

Lev-Ari, A. 8/13/2012Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stentshttps://pharmaceuticalintelligence.com/2012/08/13/coronary-artery-disease-medical-devices-solutions-from-first-in-man-stent-implantation-via-medical-ethical-dilemmas-to-drug-eluting-stents/

Lev-Ari, A. 7/18/2012Percutaneous Endocardial Ablation of Scar-Related Ventricular Tachycardia

https://pharmaceuticalintelligence.com/2012/07/18/percutaneous-endocardial-ablation-of-scar-related-ventricular-tachycardia/

Lev-Ari, A. 6/13/2012Treatment of Refractory Hypertension via Percutaneous Renal Denervation

https://pharmaceuticalintelligence.com/2012/06/13/treatment-of-refractory-hypertension-via-percutaneous-renal-denervation/

Lev-Ari, A. 6/22/2012Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS)

https://pharmaceuticalintelligence.com/2012/06/22/competition-in-the-ecosystem-of-medical-devices-in-cardiac-and-vascular-repair-heart-valves-stents-catheterization-tools-and-kits-for-open-heart-and-minimally-invasive-surgery-mis/

Lev-Ari, A. 6/19/2012Executive Compensation and Comparator Group Definition in the Cardiac and Vascular Medical Devices Sector: A Bright Future for Edwards Lifesciences Corporation in the Transcatheter Heart Valve Replacement Market

https://pharmaceuticalintelligence.com/2012/06/19/executive-compensation-and-comparator-group-definition-in-the-cardiac-and-vascular-medical-devices-sector-a-bright-future-for-edwards-lifesciences-corporation-in-the-transcatheter-heart-valve-replace/

Lev-Ari, A. 6/22/2012Global Supplier Strategy for Market Penetration & Partnership Options (Niche Suppliers vs. National Leaders)in the Massachusetts Cardiology & Vascular Surgery Tools and Devices Market for Cardiac Operating Rooms and Angioplasty Suites

https://pharmaceuticalintelligence.com/2012/06/22/global-supplier-strategy-for-market-penetration-partnership-options-niche-suppliers-vs-national-leaders-in-the-massachusetts-cardiology-vascular-surgery-tools-and-devices-market-for-car/

Lev-Ari, A. 7/23/2012Heart Remodeling by Design: Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony

https://pharmaceuticalintelligence.com/2012/07/23/heart-remodeling-by-design-implantable-synchronized-cardiac-assist-device-abiomeds-symphony/

Lev-Ari, A. (2006b). First-In-Man Stent Implantation Clinical Trials & Medical Ethical Dilemmas. Bouve College of Health Sciences, Northeastern University, Boston, MA 02115

 

Read Full Post »


Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

Curator: Aviva Lev-Ari, PhD, RN

 

@pharma_BI

@AVIVA1950

 

All 57 RETWEETS by  World Forum from LPBI’s Twitter.com handles

@pharma_BI

@AVIVA1950

 

https://twitter.com/PartnersWMIF

  

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 @AVIVA1950 Medical Devices – Prevention methods, Big data , AI, Heart Failure a role for Government like “CVD Moonshot”

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI @AVIVA1950 #WMIF17 a working artificial heart is more needed than another stent, personalized sensors (diagnostics) reimbursment

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@pharma_BI @AVIVA1950 #WMIF17 Monetizing Diagnostics is key no reimbursement for regenerative medicine, biological system vs physical system

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Bruce Rosengard: Crowd sourcing future mechanism for funding innovations vs ROI funding, Partnerships Academia/Industry

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@pharma_BI @AVIVA1950 #WMIF17 E. Edelman: Ideas start in Academia, Residential teaching is eroding, Industry needs assuming role of Academia

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Ronald Tompkins, MD: Regulatory FDA/Bureaucracy needs be non-adversarial relations with Hospitals or Academia or industry

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI @AVIVA1950 #WMIF17 Timothy Ring, CEO, Bard: corporate controlled fund for acquisions rely on Start up community for acquisitions

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI, #WMIF17 Michael Mussallem CEO, Edwards Lifesciences Selling services – heart-lung machine: Perfusion is a product and Service

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Lewis Sandy, MD UnitedHealth 30% of care cost is WASTE, eliminate!! Collaborations Pharma Devices: Data Analytics KEY

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 @AVIVA1950 Jagmeet Singh, MGH Genetic profiling for early detection, Going upstream for the Genetics and the Prevention

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Omar Ishrak, PhD CEO, Medtronic Innovations are the essence of Medical Devices development as mission in technology

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Omar Ishrak, CEO, Medtronic Training Challenge Surgical Robotic patient comfort of minimal invasive therapy, cost lower

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Omar Ishrak, CEO, Medtronic Mitral Valve – platform for new generation of diagnostics ETERNAL: recover fast outcome

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 1

More

@Pharma_BI #WMIF17 Marc Semigran Myokardia Preclinical trials for early insights for Younger patient with cardiomiopaty and older patient

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Makoto Suematsu initiative on Dementia, cases of +100 y-o without functional decline in Japan

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 @AVIVA1950 Makoto Suematsu, collaboration with NIH, Beyond the Border Masanori Aikawa AGING disease indication is novel

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Innovations from Japan leveraged in a global corporation, Bayer, Academia and Industry Partnership investment from Bayer

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 @AVIVA1950 Makoto Suematsu, Pharma’s difficulty to data access the clinical data from Academic Hospitals, gov’t IT invest

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Carsten Brunn, Bayer Osaka Innovation Center to facilitate Translational results transfer to Pharma, stem cell initiative

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI @AVIVA1950 #WMIF17 Hiroyuki Kawabata rate of CVD and HTN increased in Japan with aging population, national goal decrease BP

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI @AVIVA1950 #WMIF17 Benjamin Scirica, FDA requires PRAGMATIC TRIAL DESIGN, IDENTIFY DIFFERENT POPULATION FOR EXISTING DRUGS,

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@Pharma_BI #WMIF17 Rowe of Edwards Mitral Valve Trans catheter is the direction PATIENT ACCESS – who will benefit devices Improve Patient

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Cost of failure for AD at Eli Lilly, reduce failure rate, hedge bets to cut losses, investment may be deadend

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Offset AD prevent vs delay age of onsett is desirable, Pharma spend $70Billion on R&D, most is D NIH is R

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_BI, @AVIVA1950, Increase Research at Eli Lilly CEO, medicine will bring value, can’t apologies for drug failure, best time

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Stanley Shaw, MD, PhD Realization by physicians that monitoring Patients @Home is a TIME SAVER – tech adopted

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_BI Stanley Shaw Trusted Sources for Sharing genetic information with Academic Centers: Verily, AstraZeneca, AHA partnership

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_BI @AVIVA1950 Jonathan Rennert: histories of ECG before cardiac arrest: instruct do not drive, do not be alone at home

1 retweet

Retweet

1

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @pharma_Bi @AVIVA1950 Joe Kvedar, MD Implement technology for quality care, access and lower cost monitoring Patients while @Home

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Value of innovation at a price that allows access and lowering cost of care

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Cardiologist prescribed the medication for himself 6 month for insurance approval

0 replies1 retweet0 likes

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Norman Stockbridge, MD, PhD Director, Division of CV and Renal Products, FDA: Preserve randomization is key

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Elisabeth Björk, AstraZeneca asked Norman Stockbridge, FDA – pragmatic design avoid missing data is 12%

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Scott Wasserman, Amgen, AI will become part of Clinical Trial Design for investigational therapies and others

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Dean Li, Merck, Arrhythmia: Mutation if down played causes Arrhythmia if Overexpressed causes Arrhythmia

0 replies1 retweet0 likes

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen in CVD complex traits phynotype more determinative then genotyping vs Oncology,

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen Sean Harper, MD Investors:to Biotech – works on Oncology and on Orphan drugs

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Jean-François Formela, MD Coolest technology: CRISPR one injection reduction of effects in a genetic disease

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  May 2

More

@pharma_BI @AVIVA1950 #WMIF17 Highlights – LIVE Day 2: World Medical Innovation Forum – https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  16h16 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Ecosystem: Products, Patient Advocacy Groups and Regulators –alignment interaction among agencies: NIH, FDA

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  16h16 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Investment in Devices looks better vs CVD Drugs, Biologics are different, Nurtaceuticals some are harmful

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  16h16 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Robert Califf, Precision Medicine is over inflated except in Oncology, “in CVD, I wish to hear from you”

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  15h15 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Jessica Mega CMO Verily, Real Time monitoring, each Patient has own Portal, monitoring takes major resources

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  15h15 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Michael Mahoney: Challenges in Emerging Markets: China more regulation India – price very low expensive stent

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  15h15 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Microelectronics new direction: Endoscopy GI Pulmonary,SPINAL CORD STIMULATION: GU GI (Crohn),Neuromodulation

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Aarif Khakoo, MD Amgen 1,500,000 stroke Genetics will bring the breakthrough to atherosclerosis

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Craig Sponseller, Is triglycerides the right focus, Macrophage activation to prevent pathways resistance

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Aarif Khakoo, MD Amgen Cost is related to FAIL less – target selection is cardinal

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Clive Meanwell, Phase III needs different questions and more Phase IV needed

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Campbell Rogers, MD Clinical burden remains: Value for Patient economic value of the outcome of the

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Campbell Rogers, MD Imaging Efficiency free cost Plaque composition Coronary CT flow implication of stenosis

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  14h14 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Craig Sponseller, MD Pragmatic Clinical Trial Design: Novel Targets, collaboration of Academia and Industry

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  13h13 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons Reinvent Longitudinal Cohort Studies & Genomics sequencing – Concepts of Data Commons Analytics

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  13h13 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons 20% investigators take up 50% of the grants squeezing out the bandwidth need younger generation

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  13h13 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons, MD Pragmatic optimist in this position, scientists innovate for Patients would do it again

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  11h11 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

 

World Forum Retweeted

Aviva Lev-Ari‏ @AVIVA1950  11h11 hours ago

More

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

 

Compilation of Tweets on

@pharma_BI

and

@AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA19503h3 hours ago

 

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 2. Harnessing Big Data and Deep Learning for Clinical Decision Support

1 retweet2 likes

  1. You Retweeted

@pharma_BI‏ @Pharma_BI  3h3 hours ago

 

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

1 retweet1 like

 

  1. Aviva Lev-Ari‏ @AVIVA19503h3 hours ago

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA •… https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

 

Aviva Lev-Ari‏ @AVIVA1950  22h22 hours ago

 

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA… https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

View Tweet activity

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @Pharma_BI @AVIVA Frans van Houten CEO, Philips eICU -measure evolution to forcast 6 hours a deterioration reduction 40% of death

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF @pharma_BI @AVIVA1950 Robert Bradway Future at Amgen: Coming drug is Pharmcogenetics for atherosclerosis

LikeAviva Lev-Ari‏ @AVIVA1950  May 2

 

Robert Bradway CEO, Amgen Pay for benefit, for outcome, no pay if med does not do what it was supposed to do – REFUND patients poor outcome

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Cardiologist prescribed the medication for himself 6 month for insurance approval

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @Pharma_BI @AVIVA1950 Robert Bradway CEO, Amgen Value of innovation at a price that allows access and lowering cost of care

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

 

#WMIF17 @pharma_Bi @AVIVA1950 Joe Kvedar, MD Implement technology for quality care, access and lower cost monitoring Patients while @Home

1 retweet

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 2

More

#WMIF17 @pharma_BI @AVIVA1950 Jonathan Rennert: histories of ECG before cardiac arrest: instruct do not drive, do not be alone at home

 

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

 

#WMIF17 @pharma_BI Stanley Shaw Trusted Sources for Sharing genetic information with Academic Centers: Verily, AstraZeneca, AHA partnership

View Tweet activity

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

 

#WMIF17 @Pharma_BI @AVIVA1950 Stanley Shaw, MD, PhD Realization by physicians that monitoring Patients @Home is a TIME SAVER – tech adopted

1 retweet

 

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

 

#WMIF17 @pharma_BI, @AVIVA1950, Increase Research at Eli Lilly CEO, medicine will bring value, can’t apologies for drug failure, best time

1 retweet

  1. Aviva Lev-Ari‏ @AVIVA1950 May 2

More

#WMIF17 @Pharma_BI @AVIVA1950 Offset AD prevent vs delay age of onsett is desirable, Pharma spend $70Billion on R&D, most is D NIH is R

1 retweet

Aviva Lev-Ari‏ @AVIVA1950  May 1

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, M… https://pharmaceuticalintelligence.com/2017/05/01/highlights-of-live-day-1-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

retweet

4

Liked

14

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

1 retweet 1 like

 

Retweeted

1

Liked

1

 

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017… https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ …

 

More

https://lnkd.in/dwiwJc6 

 

Like

11

More

Merck eyes key cancer drug growth as others lose patent protection

1 retweet0 likes

 

Retweet

1

 

 

Empowering students today to create the world of tomorrow

 

 

 

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

 

 

 

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

 

 

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017… https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states …

 

 

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

 

More

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017… https://pharmaceuticalintelligence.com/2017/05/01/highlights-of-live-day-1-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states …

 

  1. World Forum Retweeted your reply

 

8h8 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

9 other Retweets

AI Newsletter liked your reply

 

8h8 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Disruptive Dozen 2. Harnessing Big Data and Deep Learning for Clinical Decision Support

  1. Sek Kathiresan MD‏ @skathire10h10 hours ago

More

Sek Kathiresan MD Retweeted Aviva Lev-Ari

If competition/judging is ‘fair’ process, how is ‘20% taking up 50%’ a problem?

Sek Kathiresan MD added,

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons 20% investigators take up 50% of the grants squeezing out the bandwidth need younger generation

3 replies0 retweets2 likes

Reply

3

Retweet

Like

2

Sek Kathiresan MD liked your reply

10h10 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Gary Gibbons 20% investigators take up 50% of the grants squeezing out the bandwidth need younger generation

Gabriel M Santibañez liked your reply

 

11h11 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Campbell Rogers, MD Imaging Efficiency free cost Plaque composition Coronary CT flow implication of stenosis

Intrepid Bio Retweeted your reply

 

12h12 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Aarif Khakoo, MD Amgen 1,500,000 stroke Genetics will bring the breakthrough to atherosclerosis

Bryan Yee Retweeted your reply

 

23h23 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Scott Wasserman, Amgen, AI will become part of Clinical Trial Design for investigational therapies and others

 

Bryan Yee and Gabriel M Santibañez liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Scott Wasserman, Amgen, AI will become part of Clinical Trial Design for investigational therapies and others

Gabriel M Santibañez Retweeted your Retweet

 

May 2

Eric TopolVerified account @EricTopol

A gluten-free diet may not be without hazard http://www.bmj.com/content/357/bmj.j1892 … potential of reduced grain intake & cardiovascular risk @bmj_latest #OA

Gabriel M Santibañez liked your Retweet

 

May 2

RISD @risd

‘Creativity is highly valued in all industries’ @virgilabloh #VirgilxRISD

 

Gabriel M Santibañez and 6 others followed you

 

May 2

World Forum Retweeted your Tweet

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Highlights – LIVE Day 2: World Medical Innovation Forum – https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%e2%80%a2-may-1-3-2017-boston-ma-%e2%80%a2-united-states/ … via @Pharma_BI

9 other Retweets

 

MB Caschetta and Michele Carbone liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen Sean Harper, MD Investors:to Biotech – works on Oncology and on Orphan drugs

Michele Carbone liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 #WMIF17 Sean Harper, MD, Amgen in CVD complex traits phynotype more determinative then genotyping vs Oncology,

Pearl Freier liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@Pharma_BI @AVIVA1950 #WMIF17 Benjamin Scirica, FDA requires PRAGMATIC TRIAL DESIGN, IDENTIFY DIFFERENT POPULATION FOR EXISTING DRUGS,

Nicole Volpe Miller liked your reply

 

May 2

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Omar Ishrak, PhD CEO, Medtronic Innovations are the essence of Medical Devices development as mission in technology

World Forum Retweeted your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Marc Semigran Myokardia Preclinical trials for early insights for Younger patient with cardiomiopaty and older patient

9 other Retweets

World Forum Retweeted your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Omar Ishrak, CEO, Medtronic Training Challenge Surgical Robotic patient comfort of minimal invasive therapy, cost lower

9 other Retweets

 

Shira Rubinoff and Mike Newkirk followed you

 

May 1

BrackenData liked your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 @AVIVA1950 Medical Devices – Prevention methods, Big data , AI, Heart Failure a role for Government like “CVD Moonshot”

BrackenData liked your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Lewis Sandy, MD UnitedHealth 30% of care cost is WASTE, eliminate!! Collaborations Pharma Devices: Data Analytics KEY

Gabriel M Santibañez liked your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 Ronald Tompkins, MD: Regulatory FDA/Bureaucracy needs be non-adversarial relations with Hospitals or Academia or industry

Smart Medicine Retweeted your reply

 

May 1

Aviva Lev-Ari @AVIVA1950

@Pharma_BI #WMIF17 @AVIVA1950 Medical Devices – Prevention methods, Big data , AI, Heart Failure a role for Government like “CVD Moonshot”

 

Read Full Post »


e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

Curator and Reporter: Aviva Lev-Ari, PhD, RN

 

https://worldmedicalinnovation.org/agenda/

 

Highlights of LIVE Day 1: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017  BOSTON, MA • UNITED STATES

https://pharmaceuticalintelligence.com/2017/05/01/highlights-of-live-day-1-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

Highlights – LIVE Day 2: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

https://pharmaceuticalintelligence.com/2017/05/02/highlights-live-day-2-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

Highlights LIVE Day 3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017 BOSTON, MA • UNITED STATES

https://pharmaceuticalintelligence.com/2017/05/03/highlights-live-day-3-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-%E2%80%A2-united-states/

Read Full Post »

Older Posts »